• Allowed for the inclusion of PORT Risk Class V subjects in the study. • Added exclusion criterion to specify restrictions associated with use of linezolid (known uncontrolled arterial hypertension, pheochromocytoma, carcinoid thyrotoxicosis) and restrictions associated with use of moxifloxacin (lactose intolerance, lactase deficiency and glucose-galactose malabsorption). • Revised to reflect that local laboratory results should be obtained within the 24 hours prior to first dose of study drug to verify entry criteria in order to more accurately assess the subject’s clinical condition at time of enrollment. • Clarified that oropharyngeal and nasopharyngeal specimens may include culture and/or PCR. • Revised to reflect C-reactive protein samples will not be collected. • Clarified that local/regional laboratory results will be used for patient care. • Clarified that systemic steroid use during the treatment period is allowed for a short duration (e.g., steroid burst). Inhaled steroids are allowed without any restriction. • Treatment regimens clarified. • Description of delafloxacin was updated to be consistent with the Investigator's Brochure. • The statistical analysis section was revised to reflect that a shift table will be not used to analyze change from baseline for physical exam findings. Worsening from baseline was to be captured as an adverse event.

• Revised inclusion 2 to be consistent with draft guidance for industry, Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment: removed "or a change in the character of the sputum", separated vital sign abnormalities from the other clinical signs and lab abnormalities. • Added exclusion of medical history of significant hypersensitivity or allergic reaction to study drug excipients in the judgment of the investigator to exclusion 1. • Revised exclusion 4 to include criteria for documenting treatment failure based on clinical evidence and not pulmonary imaging alone. • Revised exclusion 12 to include exclusion of known uncorrected hypomagnesemia at study entry. • Revised the primary efficacy endpoint definition of improvement to include no worsening of any of the other CABP symptoms as described in the references provided in the draft guidance for industry document. • Modified the suggested criteria for IV to oral switch to improved stability if vital sign indices, e.g. no worsening. • Responders definition revised to include no worsening of other symptoms. • Nonresponders definition was revised to further clarify that additional antimicrobial treatment of the current CABP infection would only meet the Nonresponders definition if the reason for treatment was due to lack of efficacy. • Failure definition revised to clarify that additional antimicrobial treatment of the current CABP infection would only meet the Failure definition if the reason for treatment was due to lack of efficacy. • Indeterminate/Missing definition revised to clarify that a response could not be determined if the subject did not complete the planned course of study therapy for reason other than lack of efficacy. • Clarified that any potential sample size recalculation would be based on pooled information across the 2 treatment arms. • Added a table that included the definitions of symptom severity: absent (0 points), mild (1), moderate (2), and severe (3).

•Procedures of chest radiography and clinical laboratory collection performed prior to the first dose of study drug. •All screening procedures performed in the 24 hour period prior to the first dose of study drug (unless otherwise noted). • Added serology testing for Chlamydia at Day 1, TOC, and Follow-up • In the PSI/PORT scoring appendix corrected a minor discrepancy in Temperature, added a converted value from BUN to urea, and added Risk Class to the scoring table. • Added a converted value from urea to BUN in the CURB-65 scoring appendix. • Primary and secondary objectives and endpoints, sample size calculations, populations and analyses were clarified for EMA submissions. • Clarifications were added to Inclusion 4 and Exclusions 4, 5, and 12. • Timing of vital signs was updated at all visits after first dose to clarify that they may be performed at any time, but should be consistent each day. • The window for the Day 7 (oral treatment) visit was updated from ± 1 day to + 1 Day so it would not coincide with the Day 5 (oral treatment) visit. • Procedures at EOT/TOC visits clarified that a CXR or CT scan is also required to be done only for lack of efficacy. • General references to “sputum specimens” were changed to “respiratory specimens” throughout the protocol • PK sections were updated to specify endpoints and analyses to be performed. • Post-Treatment Medications section updated to clarify which data should be recorded in the eCRF. • Adverse Events section updated to clarify the required time period to record data in the CRF and to note that progression of disease under study is not recorded as an AE. • All references to ICH guideline E6(R1): Good Clinical Practice were updated to (R2) to align with global regulatory requirements. • Abbreviations were added or exchanged for text throughout the protocol as per the List of Abbreviations. • Minor grammatical and formatting changes were made throughout the text